$CDNA

Hanna John Walter JR sold $116K of CDNA

Hanna John Walter JR (President and CEO) sold 4,835 shares of CareDx, Inc. (CDNA) at $24.00 ($0.12M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hanna John Walter JR
Published Jun 8, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CDNA
Neutral
medium confidence
Mentioned
$CDNA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

The disclosure adds a fresh datapoint on insider liquidity activity; because it is under a pre-arranged 10b5-1 plan, it is less likely to signal deteriorating fundamentals.

02

Market read

Insider selling is disclosed, but the 10b5-1 structure suggests limited incremental information for valuation.

03

What to watch

Traders may want to compare with prior insider sale/buy patterns and whether there are concurrent filings (e.g., other officers, 10b5-1 plan amendments) that could change interpretation.

Relevance 3/10Novelty 6/10Timing: Filed June 8, 2026 (transaction dated June 4, 2026)

Background

The article reports an SEC Form 4 insider transaction for CareDx, Inc. (CDNA) by its President and CEO.

Company-level read

Ticker impact

$CDNANeutralMedium confidence
Context

CareDx CEO Hanna John Walter Jr filed a Form 4 selling 4,835 shares (~$116k) via an open-market sale under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived unless accompanied by other news.

Evidence & confidence

The filing is a disclosed insider transaction (open-market sale) with an existing pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no stated operational/regulatory/clinical catalyst.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be purely mechanical for liquidity/tax planning, so the market may overreact relative to the true information content.

Key entities

  • CareDx, Inc.

    Company whose shares were sold by the CEO under a 10b5-1 plan.

  • Hanna John Walter Jr

    President and CEO who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CDNAMed

CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?

CareDx (CDNA) shares rose 13% to $61.37 on high volume, following a price target increase to $74 by BTIG. Q2 2026 revenue grew 52% YoY, with testing services up 61%. Q3 earnings are expected at $0.24 per share, down 14.3% YoY, and revenue at $122.35M, up 22.3% YoY. The stock has a Zacks Rank of #2 (Buy). Charles River Laboratories (CRL), another medical services company, closed up 6.2% at $294.44, with a Zacks Rank of #2 (Buy).